Cardiovascular Drugs Practice Questions

Q: Which of the following medications is known to cause increased renin levels with prolonged use?

Enalapril. ***Enalapril*** - **Enalapril** is an **ACE inhibitor** which blocks the conversion of angiotensin I to angiotensin II, leading to decreased levels of angiotensin II [1]. - Reduced angiotensin II levels remove the **negative feedback** on renin release from the juxtaglomerular cells, thus increasing renin secretion [1], [2]. *Clonidine* - Clonidine is a **central alpha-2 adrenergic agonist** that reduces sympathetic outflow from the central nervous system. - This reduction in sympathetic activity leads to a **decrease in renin release**, as sympathetic stimulation normally promotes renin secretion [3]. *Methyldopa* - Methyldopa is a **central alpha-2 adrenergic agonist** that works similarly to clonidine by reducing sympathetic tone. - It consequently causes a **decrease in plasma renin activity** due to reduced sympathetic stimulation of the juxtaglomerular apparatus [3]. *Propranolol* - Propranolol is a **non-selective beta-blocker** that blocks beta-1 receptors in the juxtaglomerular cells of the kidney. - This blockade **inhibits the release of renin** stimulated by sympathetic activity, leading to reduced renin levels [3].

Q: Which statin is considered most potent based on mg-to-mg LDL reduction capability?

Rosuvastatin. ***Rosuvastatin*** - **Rosuvastatin** is known for its high potency, achieving significant **LDL-C reduction** at relatively low doses. - It is often considered the most potent statin on a **milligram-to-milligram basis**. *Simvastatin* - **Simvastatin** is a moderate-intensity statin, not as potent as rosuvastatin or atorvastatin in reducing LDL-C. - While effective, it typically requires higher doses to achieve comparable **LDL-C reductions** seen with high-potency statins. *Pravastatin* - **Pravastatin** is a hydrophilic statin, generally considered to be of lower potency compared to other statins like rosuvastatin and atorvastatin. - It is often used in patients with **hepatic dysfunction** due to its different metabolic profile but offers less aggressive **LDL-C reduction**. *Atorvastatin* - **Atorvastatin** is a high-intensity statin, very effective in reducing LDL-C, and often used for aggressive lipid lowering. - While highly potent, **atorvastatin** is generally considered slightly less potent than **rosuvastatin** on a mg-to-mg basis, though both are used for high-intensity lipid therapy.

Q: Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?

Ezetimibe. ***Ezetimibe*** - **Ezetimibe** selectively inhibits the **Niemann-Pick C1-Like 1 (NPC1L1) protein**, which is responsible for plant sterol and cholesterol absorption in the small intestine. - This action leads to a reduction in **LDL-C** levels by decreasing the amount of cholesterol available to the liver. *Orlistat* - **Orlistat** is a **lipase inhibitor** that prevents the absorption of dietary fats by inhibiting gastric and pancreatic lipases. - While it aids in weight loss and can indirectly improve lipid profiles, its primary mechanism is *not* direct inhibition of cholesterol absorption. *Cholestyramine* - **Cholestyramine** is a **bile acid sequestrant** that binds to bile acids in the intestine, preventing their reabsorption. - This increases the excretion of bile acids, prompting the liver to synthesize more bile acids from cholesterol, thereby lowering cholesterol levels, but it does *not* directly inhibit cholesterol absorption. *Statins* - **Statins** (HMG-CoA reductase inhibitors) are considered first-line agents for lowering cholesterol by inhibiting the **rate-limiting step in cholesterol synthesis** in the liver. - Their primary action is to reduce endogenous cholesterol production, not to block cholesterol absorption from the gut.

Q: Which drug should not be given in a patient with hyperrenninemia?

None of the options. None of the options - This is the correct answer because drugs used to treat hypertension often aim to **reduce renin activity** or its effects, making them appropriate for hyperreninemia. - Hyperreninemia indicates an overactive **renin-angiotensin-aldosterone system (RAAS)**, and all the listed drug classes can be used to manage conditions associated with it [2]. *Beta blocker* - **Beta-blockers** reduce renin secretion from the **juxtaglomerular cells** by blocking beta-1 adrenergic receptors [2]. - Therefore, they are often used to *treat* conditions involving high renin levels, making them suitable rather than contraindicated. *Calcium channel blocker* - **Calcium channel blockers** reduce peripheral vascular resistance and can lower blood pressure, but they do not directly inhibit renin secretion [1]. - However, they are not contraindicated in hyperreninemia and may be used as part of a multidrug regimen to control blood pressure. *ACE inhibitor* - **ACE inhibitors** block the conversion of **angiotensin I to angiotensin II**, thus directly interrupting the RAAS pathway [1]. - This action helps to *lower* blood pressure and can be beneficial in hyperreninemia, making it a treatment rather than a contraindicated drug [1].

Q: Hypertension is not seen with which of the following?

L–dopa. ***L–dopa*** - **L-dopa** can cause **orthostatic hypotension**, a drop in blood pressure upon standing, rather than sustained hypertension. - Its primary cardiovascular side effects are usually related to **dopaminergic stimulation**, leading to arrhythmias or orthostatic changes. *Cyclosporine* - **Cyclosporine** frequently causes **hypertension** by inducing vasoconstriction, increasing sympathetic activity, and affecting renal sodium handling. - It can lead to **renal impairment**, which further contributes to blood pressure elevation. *NSAIDs* - **NSAIDs** can cause **hypertension** by inhibiting renal prostaglandin synthesis, leading to sodium and water retention. - This effect can be particularly significant in patients with pre-existing hypertension or renal dysfunction. *Erythropoietin* - **Erythropoietin** commonly causes **hypertension**, especially when there is a rapid rise in hemoglobin or hematocrit levels. - The mechanism is thought to involve increased peripheral vascular resistance and changes in nitric oxide homeostasis.

Q: What is the drug of choice for hypertension in pregnancy?

Methyldopa. ***Methyldopa*** - **Methyldopa** is considered a first-line agent because of its established safety profile for both the mother and the fetus throughout pregnancy. - It acts centrally as an **alpha-2 adrenergic agonist**, reducing sympathetic outflow and thereby lowering blood pressure. *Enalapril* - **Angiotensin-converting enzyme (ACE) inhibitors** like Enalapril are contraindicated in pregnancy due to their association with **fetal renal abnormalities**, **oligohydramnios**, and **growth restriction**, especially in the second and third trimesters. - Their use can lead to **fetal hypotension** and potentially **fetal death**. *Verapamil* - **Calcium channel blockers** like Verapamil are generally considered second-line agents for hypertension in pregnancy. - While generally safer than ACE inhibitors, **Labetalol** and **Nifedipine** are often preferred among calcium channel blockers, and **Methyldopa** has a longer track record of safety. *Furosemide* - **Diuretics** like Furosemide are generally not recommended for chronic hypertension in pregnancy as they can **reduce plasma volume** and potentially impair placental perfusion. - They are primarily used in cases of **pulmonary edema** or severe fluid overload, rather than routine management of hypertension.

Q: A 50-year-old male with type 2 diabetes mellitus is found to have a 24-hour urinary albumin level of 250 mg. Which of the following drugs may be used to retard the progression of renal disease?

Enalapril. ***Enalapril*** - **Enalapril**, an ACE inhibitor, is indicated for **diabetic nephropathy** because it reduces intraglomerular pressure and proteinuria, thereby retarding the progression of renal disease. - Its nephroprotective effects are mediated through effects on the **renin-angiotensin-aldosterone system**. *Hydrochlorothiazide* - **Hydrochlorothiazide** is a thiazide diuretic primarily used for hypertension and edema, but it lacks the specific **renoprotective effects** of ACE inhibitors in diabetic nephropathy. - While it can lower blood pressure, it does not directly reduce **proteinuria** or slow the progression of diabetic kidney disease as effectively as ACE inhibitors. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that blocks sodium channels in the collecting duct and is primarily used to prevent **hypokalemia**, often in combination with other diuretics. - It does not offer the **glomerular hemodynamic benefits** or antiproteinuric effects necessary to retard the progression of diabetic renal disease. *Aspirin* - **Aspirin** is an antiplatelet agent used for cardiovascular protection, and while cardiovascular disease is common in diabetes, it does not have a direct role in **retarding the progression of renal disease**. - Its primary mechanism of action involves **antiplatelet aggregation** and anti-inflammatory effects, not modification of renal function in nephropathy.

Q: Which of the following is the most beta-1 selective antagonist?

Nebivolol. ***Nebivolol*** - **Nebivolol** is known for its high **beta-1 selectivity** and additional **nitric oxide-mediated vasodilation** properties. - This high selectivity contributes to a reduced incidence of bronchospasm compared to less selective beta-blockers. *Acebutolol* - **Acebutolol** is a **cardioselective** beta-blocker with **intrinsic sympathomimetic activity (ISA)**, meaning it can partially stimulate beta-receptors. - While selective for beta-1, its selectivity is not as high as nebivolol. *Atenolol* - **Atenolol** is a **cardioselective** beta-blocker that primarily antagonizes beta-1 receptors. - Its selectivity is moderate and generally lower than that of nebivolol. *Metoprolol* - **Metoprolol** is also a **cardioselective** beta-blocker, meaning it preferentially blocks beta-1 receptors at lower doses. - Its beta-1 selectivity is not as pronounced as that of nebivolol, and it can lose selectivity at higher doses.

Q: Which of the following statements is MOST accurate about sotalol?

It is non selective Beta blocker. ***It is non selective Beta blocker*** - Sotalol is classified as a **Class III antiarrhythmic** due to its **potassium channel blocking activity**, but it also possesses significant **non-selective beta-adrenergic blocking** properties (both β1 and β2). - This **dual mechanism** makes this the most comprehensive and fundamental description of sotalol's pharmacology. - The **beta-blocking effect** contributes to its antiarrhythmic efficacy, particularly in atrial arrhythmias. *It prolongs the action potential duration throughout the heart* - This statement is **factually correct** - sotalol does prolong APD throughout the heart via **Class III potassium channel blocking activity**. - However, this describes only ONE mechanism of action, whereas the correct answer captures its **non-selective beta-blocking property** which is equally fundamental to its classification. *Polymorphic ventricular tachycardia is a common problem* - **Torsades de Pointes** (polymorphic VT) is indeed a **known and serious adverse effect** of sotalol due to **QT interval prolongation**. - However, the word "common" is somewhat misleading - the incidence is approximately **2-4%**, which while significant, is not considered "common" in clinical terms. - This risk is especially elevated in patients with **electrolyte imbalances**, **bradycardia**, or concurrent use of other **QT-prolonging drugs**. *It is primarily excreted by the kidneys* - This statement is **factually correct** - sotalol undergoes **80-90% renal elimination** as unchanged drug with minimal hepatic metabolism. - **Dose adjustment is required in renal impairment**, making this clinically important. - However, like option 2, this describes a pharmacokinetic property rather than the core pharmacodynamic classification of the drug.

Q: What is the mechanism of action of beta-blockers in the treatment of hypertension?

Decreasing heart rate and contractility. ***Decreasing heart rate and contractility*** - **Beta-blockers** primarily work by blocking the effects of **catecholamines** (like epinephrine and norepinephrine) on **beta-adrenergic receptors** in the heart. - This leads to a reduction in **heart rate** and the **force of myocardial contraction**, thereby decreasing cardiac output and blood pressure. *Dilating peripheral blood vessels* - This is the primary mechanism of action for **alpha-blockers** and some **calcium channel blockers**, not typical beta-blockers. - While some **beta-blockers** (e.g., carvedilol, labetalol) also have **alpha-blocking activity** that causes vasodilation, it's not their main antihypertensive mechanism. *Increasing sodium and water retention* - This effect is actually a common side effect or a compensatory mechanism seen with some other antihypertensive drugs, but it is **not** the mechanism of action of beta-blockers. - Diuretics, for example, work by **reducing sodium and water retention**. *Blocking angiotensin-converting enzyme* - This describes the mechanism of action of **ACE inhibitors** (e.g., enalapril, lisinopril), which prevent the conversion of **angiotensin I to angiotensin II**. - This leads to vasodilation and reduced aldosterone secretion, which is distinct from how beta-blockers work.

Question 1

Which of the following medications is known to cause increased renin levels with prolonged use?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Methyldopa

Answer

Propranolol

Question 2

Which statin is considered most potent based on mg-to-mg LDL reduction capability?

Accepted Answer

Rosuvastatin

Answer

Simvastatin

Answer

Pravastatin

Answer

Atorvastatin

Question 3

Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?

Accepted Answer

Ezetimibe

Answer

Orlistat

Answer

Cholestyramine

Answer

Statins

Question 4

Which drug should not be given in a patient with hyperrenninemia?

Accepted Answer

None of the options

Answer

Beta blocker

Answer

Calcium channel blocker

Answer

ACE inhibitor

Question 5

Hypertension is not seen with which of the following?

Accepted Answer

L–dopa

Answer

NSAIDs

Answer

Erythropoietin

Answer

Cyclosporine

Question 6

What is the drug of choice for hypertension in pregnancy?

Accepted Answer

Methyldopa

Answer

Verapamil

Answer

Furosemide

Answer

Enalapril

Question 7

A 50-year-old male with type 2 diabetes mellitus is found to have a 24-hour urinary albumin level of 250 mg. Which of the following drugs may be used to retard the progression of renal disease?

Accepted Answer

Enalapril

Answer

Amiloride

Answer

Aspirin

Answer

Hydrochlorothiazide

Question 8

Which of the following is the most beta-1 selective antagonist?

Accepted Answer

Nebivolol

Answer

Acebutolol

Answer

Atenolol

Answer

Metoprolol

Question 9

Which of the following statements is MOST accurate about sotalol?

Accepted Answer

It is non selective Beta blocker

Answer

Polymorphic ventricular tachycardia is a common problem

Answer

It prolongs the action potential duration throughout the heart.

Answer

It is primarily excreted by the kidneys.

Question 10

What is the mechanism of action of beta-blockers in the treatment of hypertension?

Accepted Answer

Decreasing heart rate and contractility

Answer

Dilating peripheral blood vessels

Answer

Increasing sodium and water retention

Answer

Blocking angiotensin-converting enzyme

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?